Drug intelligence / Profile preview

STAT-401a

Development stage: Unknown
Lead developer: Statera BioPharma
Modality: Peptides, Small Molecules
Administration: Injectable, Subcutaneous

Overview

STAT-401a is an investigational injectable pentapeptide drug developed by Statera Biopharma. It is designed as an immunomodulatory agent, with its primary mechanism of action believed to involve modulation of immune system activity. The drug is being targeted for the treatment of Crohn's disease and potentially other autoimmune or inflammatory conditions. As a peptide-based therapy, it aims to restore immune balance rather than broadly suppressing immune function[2].

Beyond the preview

Go deeper on STAT-401a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAT-401a.

Explore the full profile